Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
J&J, ViiV Co-developed Long-Acting HIV Treatment Gets FDA Approval For Treating Adolescents
Johnson & Johnson's(NYSE:JNJ) Janssen unit said the U.S. Food and Drug Administration has approved Cabenuva (cabotegravir and rilpivirine) for the treatment of HIV-1 in virologically suppressed adolescents, who are 12 years of age or older, weigh at least 35 kg and are on a stable antiretroviral regimen, with no history of treatment failure, nor known or suspected resistance to either cabotegravir or rilpivirine.
Cabenuva has been...
ログインすると全部閲覧できます。
ログイン